Clinical trials: Bladder
Prostate Cancer, Urinary Incontinence, Urge
Effects of Urinary Bladder Hypertrophy on Urge Urine Incontinence After Radical Prostatectomy
This study is designed to evaluate men before radical prostatectomy for the incidence of Overactive Bladder (OAB), as well as urge urine incontinence (UUI) development after the surgery.
- Conditions
- Prostate Cancer, Urinary Incontinence, Urge, Incontinence, Prostatectomy
- Trial name
- NCT03061760
- Testing
- Radical prostatectomy, Initial evaluation, Evaluation after 1,3,6,9,12 months
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Collegium Medicum w Bydgoszczy
Recurrent Cystitis
Efficacy of IARULIL® in the Treatment of Recurrent Cystitis Refractory to Escherichia Coli Extract
The purpose of this study is to evaluate the efficacy of Combined Intravesical Therapy With Hyaluronic Acid and Chondroitin Sulphate in the Treatment of Recurrent Cystitis Refractory to Escherichia Coli Extract
- Trial name
- NCT02366676
- Testing
- hyaluronic acid and chondroitin sulphate
- Where
- South Korea
- Volunteers
- 105 people
- Sponsor
- Samsung Medical Center
Bladder Neoplasms
Mycobacterial Cell Wall-DNA Complex in Treatment of BCG-refractory Patients With Non-muscle Invasive Bladder Cancer
The purpose of this study is to determine the efficacy and safety of intravesical Mycobacterial Cell Wall-DNA Complex (MCC) in patients with non-muscle invasive transitional cell carcinoma (papillary tumors and/or carcinoma in…
- Trial name
- NCT00406068
- Testing
- Mycobacterial cell wall-DNA complex
- Where
- 31 sites in United States, Canada
- Volunteers
- 129 people
- Sponsor
- Bioniche Life Sciences Inc.
Bladder Carcinoma Infiltrating the Muscle of the Bladder Wall, Stage II Bladder Cancer AJCC v8
Avelumab in Combination With Fluorouracil and Mitomycin or Cisplatin and Radiation Therapy in Treating Participants With Muscle-Invasive Bladder Cancer
This phase II trial studies the side effects of avelumab and how well it works in combination with fluorouracil and mitomycin or cisplatin and radiation therapy in treating participants with muscle-invasive bladder cancer.
- Conditions
- Bladder Carcinoma Infiltrating the Muscle of the Bladder Wall, Stage II Bladder Cancer AJCC v8, Stage II Renal Pelvis Cancer AJCC v8, Stage II Ureter Cancer AJCC v8
- Trial name
- NCT03617913
- Testing
- Avelumab, Cisplatin, Fluorouracil
- Where
- 3 sites in United States
- Volunteers
- 2 people
- Sponsor
- Mayo Clinic
Overactive Bladder (OAB)
A Registry Study of Patients Initiating a Course of Drug Therapy for Overactive Bladder in Taiwan, Korea and China
The purpose of this study is to observe and describe treatment patterns, like Overactive Bladder (OAB) treatment discontinuation, switching to other therapies and persistence of OAB therapies in routine clinical practice.
- Trial name
- NCT03572231
- Testing
- mirabegron, solifenacin, darifenacin
- Where
- 15 sites in South Korea, Taiwan
- Volunteers
- 805 people
- Sponsor
- Astellas Pharma Singapore Pte. Ltd.
Bladder Cancer
Prospective Study of Adjuvant Radiotherapy in High Risk Bladder Cancer.
This prospective interventional study aims at evaluating the safety and efficacy of an adjuvant radiation treatment in cases of muscle-invasive bladder cancer, submitted to radical cystectomy and presenting clinic-pathological…
- Trial name
- Bladder-Aid (NCT03718741)
- Testing
- Radiotherapy +/- CT
- Where
- Italy
- Volunteers
- 7 people
- Sponsor
- Istituto Clinico Humanitas
Muscle-Invasive Bladder Carcinoma
NEO-BLAST: Neoadjuvant Therapy for Bladder Cancer Followed by Active Surveillance vs Treatment
Invasive bladder cancer is managed with neoadjuvant therapy followed by bladder removal (cystectomy). Research shows that approximately 40% of patient will have no remaining cancer left in their bladder after completion of the…
- Trial name
- NEO-BLAST (NCT06537154)
- Testing
- Active Surveillance, Control arm - Definitive bladder treatment
- Where
- Canada
- Volunteers
- 688 people
- Sponsor
- Peter Black
Bladder Urothelial Carcinoma
The Role of Pyruvate Kinase M2 in Growth, Invasion and Drug Resistance in Human Urothelial Carcinoma
Bladder urothelial carcinoma (UC) is a common malignancy and the incidence is increasing by years in Taiwan. Chemoresistance was inevitable in treatment of metastatic disease and lead to the ominous outcomes.
- Trial name
- NCT01968928
- Where
- Taiwan
- Volunteers
- 25 people
- Sponsor
- National Taiwan University Hospital
Lower Urinary Tract Symptoms, Cystometry
Reproductibility of Cystometry in Multiple Sclerosis Patient
This study evaluates the reproductibility (quantitative and qualitative) of cystometry in mutiple sclerosis patients.
- Conditions
- Lower Urinary Tract Symptoms, Cystometry, Multiple Sclerosis, Overactive Bladder
- Trial name
- NCT03451175
- Where
- France
- Volunteers
- 31 people
- Sponsor
- Pierre and Marie Curie University
Overactive Bladder Syndrome
Study of V117957 in Overactive Bladder Syndrome
The purpose of this study is to evaluate the safety, tolerability and efficacy of V117957 in subjects with overactive bladder syndrome, compared to placebo.
- Trial name
- NCT06024642
- Testing
- V117957
- Where
- 12 sites in United States
- Volunteers
- 51 people
- Sponsor
- Imbrium Therapeutics
Bladder Cancer
Single Subject Neratinib in Bladder Cancer (NRR)
This study will be a single subject study to evaluate the efficacy of the HER2 kinase inhibitor, neratinib, in a patient with metastatic bladder cancer harboring a HER2-GRB7 gene fusion.
- Trial name
- NCT01956253
- Testing
- Neratinib
- Where
- United States
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Muscle-invasive Bladder Cancer
Impact of Positron Emission Tomography (PET) Imaging in Muscle-invasive Urothelial Carcinoma of the Bladder Staging
Bladder cancer is the fifth most common cancer in Canada and there has been relatively little progress in altering its clinical course over the last three decades.
- Trial name
- PET MUSE (NCT02462239)
- Testing
- Whole-body FDG PET-CT
- Where
- 6 sites in Canada
- Volunteers
- 292 people
- Sponsor
- Ontario Clinical Oncology Group (OCOG)
Recurrent Urinary Tract Infections
Bacterial Interference for Preventing Recurrent Urinary Tract Infection - New Ways of Treatment
Urinary tract infection (UTI) is one of the most common bacterial infections worldwide. It affects 150 million people annually. Treatment of patients with UTI entails a high consumption of antibiotics and large social and health…
- Trial name
- BIrUTI (NCT04846803)
- Testing
- ABU bladder lavage, Saline bladder lavage
- Where
- 2 sites in Denmark
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Odense University Hospital
Bladder Cancer
Effect of Dietary, Lifestyle, and Environmental Factors on Patients With Early-Stage Bladder Cancer
RATIONALE: Learning about the long-term effects of dietary, lifestyle, and environmental factors on the risk of cancer progression and recurrence may help the study of bladder cancer in the future.
- Trial name
- NCT00553566
- Testing
- medical chart review, questionnaire administration, study of socioeconomic and demographic variables
- Where
- United Kingdom
- Volunteers
- 1,600 people
- Sponsor
- University of Birmingham
MIBC, mpMRI
Early Prediction of Neoadjuvant Chemotherapy Response in Bladder Cancer Using Quantitative Multiparametric MRI
Bladder cancer is a prevalent malignancy globally, with muscle-invasive disease having a five-year survival rate below 50%. Neoadjuvant chemotherapy (NAC) before radical cystectomy has shown efficacy for resectable…
- Conditions
- MIBC, mpMRI, NAC
- Trial name
- mpMRI (NCT07202845)
- Testing
- Multiparametric Magnetic Resonance Imaging (mpMRI)
- Where
- Egypt
- Volunteers
- 39 people
- Sponsor
- Assiut University
Carcinoma, Transitional Cell
Evaluation of Oxaliplatin and Gemcitabine in Patients With Metastatic Bladder Cancer
This phase II trial evaluated the impact of Oxaliplatin and Gemcitabine in patients with recurrent or advanced transitional cell carcinoma of the bladder.
- Trial name
- NCT04039867
- Testing
- Oxaliplatin with Gemcitabine
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of California, Irvine
Bladder Cancer
Durvalumab Plus Olaparib Administered Prior to Surgery of Resectable Urothelial Bladder Cancer (NEODURVARIB)
The standard of care for muscle-invasive bladder cancer (MIBC) is radical cystectomy, which is rarely curative. Platinum-based neoadjuvant chemotherapy is associated with an improvement in Overall Survival (OS), but only a few…
- Trial name
- NEODURVARIB (NCT03534492)
- Testing
- Durvalumab, Olaparib
- Where
- 10 sites in Spain
- Volunteers
- 29 people
- Sponsor
- Spanish Oncology Genito-Urinary Group
Breast Cancer, Lung Cancer
Sample Collection for Ongoing Research and Product Evaluation Study
The SCORE study is a prospective, multi-site clinical trial designed to collect blood and tissue samples, along with relevant clinical data, from participants diagnosed with various solid tumors.
- Conditions
- Breast Cancer, Lung Cancer, Muscle Invasive Bladder Cancer, Rectal Cancer
- Trial name
- SCORE (NCT07318051)
- Where
- United States
- Volunteers
- 9,600 people
- Sponsor
- Natera, Inc.
Overactive Bladder Syndrome
Post-treatment Novmalized Urodynamiz Findings as the Golden Standard of Objective Cure for Female Overactive Bladder Patients Receiving Antimuscarinic Drug
Post-treatment Novmalized Urodynamiz Findings as the Golden Standard of Objective Cure for Female Overactive Bladder Patients Receiving Antimuscarinic Drug and Its Conelations With Voiding Diary, King's Health Quentionaire…
- Trial name
- NCT01627145
- Testing
- Solifenacin
- Where
- Taiwan
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
Urinary Bladder, Overactive
A Study to Evaluate the Efficacy of Tolterodine on Specific Symptoms in Adult Patients With Overactive Bladder.
The purpose of this study is to evaluate the efficacy and safety of tolterodine in impacting the primary symptom or complaint of patients with OAB.
- Trial name
- NCT00645281
- Testing
- tolterodine extended release
- Where
- 96 sites in United States
- Volunteers
- 896 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.